Kronox Lab Sciences Ltd

Kronox Lab Sciences Ltd has responded to a clarification request from the stock exchange regarding a significant increase in its share volume. The company stated that it has consistently disclosed all material information as per SEBI regulations. Kronox Lab Sciences further clarified that the company's management is not connected to the recent surge in share volume. They reiterated their commitment to regulatory compliance.

Kronox Lab Sciences Ltd has announced the closure of its trading window for the quarter ending June 30, 2026. This measure, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, restricts all designated persons from trading in the company's equity shares. The window will reopen 48 hours after the announcement of the unaudited financial results for the said quarter, which will be approved in an upcoming Board Meeting. The date of the Board Meeting will be communicated in due course.

Kronox Lab Sciences Ltd's board approved the audited standalone financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹2,613.11 Lacs for the quarter ended March 31, 2026, and ₹10,122.00 Lacs for the year ended March 31, 2026. Net profit after tax stood at ₹800.21 Lacs for the quarter and ₹2,766.00 Lacs for the year. The board has declared a final dividend of 5% (₹0.50 per share) on equity shares of ₹10 each for the year 2025-26.

Kronox Lab Sciences Ltd's board approved the audited standalone financial results for the quarter and financial year ended March 31, 2026. They recommended a dividend of 5% (₹0.50 per share) subject to member approval. The meeting, held on May 21, 2026, commenced at 4:00 p.m. and concluded at 5:00 p.m. The company reported revenue of ₹10,122.00 Lacs and profit after tax of ₹3,730.30 Lacs for the year ended March 31, 2026.

Kronox Lab Sciences Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any, on equity shares for the financial year ended March 31, 2026. The trading window for the company's securities remains closed for directors, officers, and designated employees from April 1, 2026, until 48 hours after the declaration of the results.

Kronox Lab Sciences Ltd has scheduled a Board of Directors meeting on May 20, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any, on equity shares for the financial year ended March 31, 2026. The trading window for the company's securities remains closed for Directors, Officers, and designated employees from April 01, 2026, until 48 hours after the declaration of the results.

Kronox Lab Sciences Ltd has issued a clarification regarding the movement in its share price, stating that it has always disclosed all material information to the stock exchange as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is not aware of the reason for the significant movement in its share price and reiterates its commitment to adhere to all compliances required under the Listing Regulations and other applicable laws.

Kronox Lab Sciences Ltd has announced the closure of the trading window for the quarter and year ending March 31, 2026. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed for all designated persons as defined under the Company’s Code of Conduct from Wednesday, 1st April, 2026. It will open 48 hours after the announcement of the Audited Financial Results of the quarter and year ending on 31st March, 2026 by the Board of Directors in an upcoming Board Meeting. The date of the Board Meeting will be communicated in due course.

Kronox Lab Sciences Ltd. announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations for the quarter was Rs. 2,527.40 Lakhs, representing a 5.2% increase from the same period in the previous year. The net profit for the quarter was Rs. 1,915.19 Lakhs, a significant increase from the Rs. 1,546.71 Lakhs reported in the same period last year. The company's total income for the quarter stood at Rs. 2,640.85 Lakhs, while the total expenses were Rs. 1,965.79 Lakhs. The company's earnings per equity share for the quarter were Rs. 37.10, up from Rs. 32.10 in the same period last year. The board of directors has reviewed and approved these results.

Kronox Lab Sciences Ltd. held a board meeting on February 14, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 2,553.32 Lakhs for the quarter and 7,814.14 Lakhs for the nine months ended. The net profit for the quarter is 1,915.19 Lakhs and 2,546.71 Lakhs for the nine months ended. The company has one reportable segment under Ind AS-108 on 'Operating Segments', which is manufacturing of High Purity Specialized Fine chemical.